MLL translocation in two castration-resistant prostate cancer patients

被引：0

作者：

Chowdry, Rajasree Pia ^{[1
]}

Ledet, Elisa ^{[2
]}

Asinghe, Lahiru Ran. ^{[3
]}

Sartor, Alton Oliver ^{[2
]}

机构：

[1] Tulane Univ, Sect Hematol Med Oncol, Hematol Oncol, New Orleans, LA USA

[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA

[3] Tulane Univ, Sch Med, New Orleans, LA 70112 USA

来源：

CANADIAN JOURNAL OF UROLOGY | 2016年 / 23卷 / 05期

关键词：

prostate cancer; castration-resistant; MLL; bone marrow; FUSION PROTEINS; MENIN; LEUKEMIA;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The mixed-lineage leukemia (MLL) protein acts as a histone methyltransferase regulating multiple genetic elements. Rearrangements of the MLL gene result in expression of MLL fusion proteins that occur in some acute leukemias and are associated with poor prognosis. The MLL protein complex has been shown to interact with the androgen receptor via the MLL-menin subunit, thus promoting gene activation. The presence of MLL translocation has not been previously reported in patients with castrate resistant prostate cancer (CRPC). We describe two cases of metastatic CRPC with a translocation in the MLL gene detected by a specific fluorescent in situ hybridization (FISH) assay. Both patients had an aggressive course and succumbed to the illness.

引用

页码：8483 / 8486

页数：4

共 50 条

[21] Strategy in advanced castration-resistant prostate cancer [J].

Gross-Goupil, Marine ;

Roca, Sophie ;

Pasticier, Gilles ;

Ravaud, Alain .

BULLETIN DU CANCER, 2012, 99 :S37-S45

[22] Abiraterone acetate in castration-resistant prostate cancer [J].

Iacovelli, Roberto ;

Palazzo, Antonella ;

Procopio, Giuseppe ;

Gazzaniga, Paola ;

Cortesi, Enrico .

ANTI-CANCER DRUGS, 2012, 23 (03) :247-254

[23] The Molecular Evolution of Castration-resistant Prostate Cancer [J].

Ceder, Yvonne ;

Bjartell, Anders ;

Culig, Zoran ;

Rubin, Mark A. ;

Tomlins, Scott ;

Visakorpi, Tapio .

EUROPEAN UROLOGY FOCUS, 2016, 2 (05) :506-513

[24] Sequencing Treatment for Castration-Resistant Prostate Cancer [J].

Handy, Catherine E. ;

Antonarakis, Emmanuel S. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)

[25] Sequencing Treatment for Castration-Resistant Prostate Cancer [J].

Catherine E. Handy ;

Emmanuel S. Antonarakis .

Current Treatment Options in Oncology, 2016, 17

[26] Current, new and novel therapy for castration-resistant prostate cancer [J].

Gaya, Josep M. ;

Ahallal, Youness ;

Sanchez-Salas, Rafael ;

Barret, Eric ;

Rozet, Francois ;

Macek, Marc Galiano Peter ;

Durand, Matthieu ;

Cerruti, Jennifer ;

Prapotnich, Dominique ;

Ropert, Stanislas ;

Bennamoun, Mostefa ;

Cathelineau, Xavier .

EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (07) :819-827

[27] The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer [J].

Tsao, Che-Kai ;

Cutting, Elena ;

Martin, Jacob ;

Oh, William K. .

THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (03) :97-104

[28] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer [J].

Sausan Abouharb ;

Paul G. Corn .

Current Oncology Reports, 2013, 15 :217-223

[29] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer [J].

Abouharb, Sausan ;

Corn, Paul G. .

CURRENT ONCOLOGY REPORTS, 2013, 15 (03) :217-223

[30] Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer [J].

Lorente, David ;

Fizazi, Karim ;

Sweeney, Christopher ;

de Bono, Johann S. .

EUROPEAN UROLOGY FOCUS, 2016, 2 (05) :488-498

← 1 2 3 4 5 →